论文部分内容阅读
目的观察肿瘤免疫激活剂预防肝细胞癌(HCC)切除术后复发的效果。方法1999年3月2003年6月80例HCC根治切除术后患者采用随机,对照的方法分为免疫激活剂组和对照组,进行肿瘤免疫激活剂注射,该免疫激活剂成分包括固定的HCC细胞或组织碎片、粒细胞-巨噬细胞集落刺激因子和白细胞介素-2的生物可降解缓释微球和免疫辅助物。观察肿瘤免疫激活剂皮内接种激发的迟发型超敏反应(DTH)和预防HCC切除术后复发的效果。结果免疫激活剂组中8例和对照组中5例失访,平均随访34.3 个月(15-55个月)。在HCC免疫激活剂治疗中未见不良反应。32例患者中23例出现抗HCC DTH阳性。免疫激活剂组术后1、2、3年复发率分别为12.6%、35.9%、54.0%; 而对照组HCC切除术后1、2、3年复发率分别为31.6%、61.3%、72.1%,免疫激活剂组的复发率低于对照组(P<0.05)。结论这种细胞因子缓释微球的肿瘤免疫激活剂具有很强的抗肿瘤和预防肝癌切除术后复发的效果。
Objective To observe the effect of tumor immune activator in preventing recurrence of hepatocellular carcinoma (HCC) resection. Methods March 1999 March 2003 80 cases of patients with HCC after radical resection using randomized and controlled methods were divided into immune activator group and control group, the tumor immune activator injection, the immune activator components include fixed HCC cells Or tissue fragments, granulocyte-macrophage colony-stimulating factor and interleukin-2 biodegradable microspheres and immune adjuvants. To observe the effect of tumor immunostimulant intradermal inoculation on delayed type hypersensitivity (DTH) and prevention of recurrence after HCC resection. Results In the immunosuppressant group, 5 cases were lost in 8 cases and control group, with an average follow-up of 34.3 months (15-55 months). No adverse reactions were seen in the treatment of HCC immune activators. Twenty-three of 32 patients developed anti-HCC DTH positive. The recurrence rates at 1, 2 and 3 years after operation were 12.6%, 35.9% and 54.0% in the immunosuppressant group, respectively, while those in the control group at 1, 2 and 3 years were 31.6%, 61.3% and 72.1% , And the recurrence rate of immune activator group was lower than that of control group (P <0.05). Conclusion The tumor immune activator of this cytokine sustained-release microspheres has strong anti-tumor effect and prevention of recurrence after liver cancer resection.